Pegfilgrastim Prefilled Syringes and Polatuzumab Vedotin-piiq
Determining the interaction of Pegfilgrastim Prefilled Syringes and Polatuzumab Vedotin-piiq and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells. MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents. References "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA.
Professional:ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.
- "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA.
Generic Name: pegfilgrastim
Brand name: Fulphila, Neulasta, Neulasta Onpro Kit, Udenyca, Neulasta Delivery Kit
Synonyms: Pegfilgrastim
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pegfilgrastim Prefilled Syringes-Polio vaccine, inactivated
- Pegfilgrastim Prefilled Syringes-Poliovirus Vaccine (Inactivated)
- Pegfilgrastim Prefilled Syringes-Poliovirus vaccine, inactivated Injection
- Pegfilgrastim Prefilled Syringes-Polivy
- Pegfilgrastim Prefilled Syringes-Polmon
- Pegfilgrastim Prefilled Syringes-Polocaine
- Polatuzumab Vedotin-piiq-Pegfilgrastim Subcutaneous
- Polatuzumab Vedotin-piiq-Pegfilgrastim-cbqv
- Polatuzumab Vedotin-piiq-Pegfilgrastim-jmdb
- Polatuzumab Vedotin-piiq-Pegfilgrastim-jmdb Subcutaneous
- Polatuzumab Vedotin-piiq-Peginesatide Injection
- Polatuzumab Vedotin-piiq-Peginterferon alfa-2a